Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
Takada M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Ohno S, Ishiguro H, Kanbayashi C, Miyamoto T, Hagiwara Y, Toi M. Takada M, et al. Among authors: kanbayashi c. Breast Cancer Res Treat. 2023 Dec;202(3):485-496. doi: 10.1007/s10549-023-07099-4. Epub 2023 Sep 7. Breast Cancer Res Treat. 2023. PMID: 37676450 Free PMC article.
Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Tokuda Y, Saji S, Iwata H. Niikura N, et al. Among authors: kanbayashi c. Breast Cancer Res Treat. 2014 Aug;147(1):103-12. doi: 10.1007/s10549-014-3090-8. Epub 2014 Aug 9. Breast Cancer Res Treat. 2014. PMID: 25106661
Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
Hayashi N, Niikura N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Yamauchi H, Saji S, Iwata H. Hayashi N, et al. Among authors: kanbayashi c. Breast Cancer Res Treat. 2015 Jan;149(1):277-84. doi: 10.1007/s10549-014-3237-7. Epub 2014 Dec 21. Breast Cancer Res Treat. 2015. PMID: 25528021
Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study.
Shigekawa T, Osaki A, Sekine H, Sato N, Kanbayashi C, Sano H, Takeuchi H, Ueda S, Nakamiya N, Sugitani I, Sugiyama M, Shimada H, Hirokawa E, Takahashi T, Saeki T. Shigekawa T, et al. Among authors: kanbayashi c. BMC Cancer. 2015 Apr 10;15:253. doi: 10.1186/s12885-015-1289-7. BMC Cancer. 2015. PMID: 25884795 Free PMC article.
Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer.
Ogiya R, Niikura N, Kumaki N, Yasojima H, Iwasa T, Kanbayashi C, Oshitanai R, Tsuneizumi M, Watanabe KI, Matsui A, Fujisawa T, Saji S, Masuda N, Tokuda Y, Iwata H. Ogiya R, et al. Among authors: kanbayashi c. Oncotarget. 2017 Oct 27;8(61):103671-103681. doi: 10.18632/oncotarget.22110. eCollection 2017 Nov 28. Oncotarget. 2017. PMID: 29262592 Free PMC article.
Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.
Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Sato N, et al. Among authors: kanbayashi c. Cancer Med. 2018 Jul;7(7):3044-3056. doi: 10.1002/cam4.1600. Epub 2018 Jun 14. Cancer Med. 2018. PMID: 29905023 Free PMC article.
Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study.
Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, Saji S, Sasano H, Morita S, Ohno S, Toi M. Sato N, et al. Among authors: kanbayashi c. Cancer Med. 2019 Sep;8(12):5468-5481. doi: 10.1002/cam4.2423. Epub 2019 Jul 30. Cancer Med. 2019. PMID: 31361400 Free PMC article. Clinical Trial.
Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.
Tanaka K, Masuda N, Hayashi N, Sagara Y, Hara F, Kadoya T, Matsui A, Miyazaki C, Shien T, Tokunaga E, Hayashi T, Niikura N, Maeda S, Komoike Y, Bando H, Kanbayashi C, Iwata H. Tanaka K, et al. Among authors: kanbayashi c. Breast Cancer. 2021 Jul;28(4):896-903. doi: 10.1007/s12282-021-01225-0. Epub 2021 Feb 18. Breast Cancer. 2021. PMID: 33599914 Free PMC article.
40 results